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Recently there has been discussion on the value of pro-
longed thromboprophylaxis after elective hip surgery to
prevent thromboembolic complications up to one month.
Continuing low molecular weight heparin for one
month can significantly reduce the frequency of veno-
graphically-proven deep vein thrombosis (DVT). How
this will influence health economics has hitherto not
been evaluated. Data on costs and effect from a ran-
domized comparison between 10 and 30 days of once
daily low molecular weight heparin (enoxaparin) were
used in a cost-effectiveness study. Data on treatment
costs were based on patients actually treated for DVT
within the randomized study. Various sensitivity analy-
ses were performed. In the study both phlebographically
detected and clinically manifested venous thromboem-
bolism were registered. By using costs from the health
care system in Sweden it could be shown that the cost
was 6,075 Swedish Krona (SEK) per phlebographic
DVT avoided and 13,184 Swedish Krona (SEK) per
clinical DVT avoided. If more than 50% of the patients
managed to self-administer the low molecular weight
heparin injections, the use of prolonged prophylaxis is
cost-effective. Prolonged prophylaxis with the low mo-
lecular weight heparin enoxaparin after elective hip ar-
throplasty is cost-effective provided that at least 50%
of the patients can administer the subcutaneous injec-
tions themselves.
 
Introduction
 
In four recent studies, the frequency of veno-
graphic deep vein thrombosis (DVT) for approxi-
mately one month after elective hip replacement
has been significantly reduced when prolonged
prophylaxis was given, compared with conven-
tional duration of prophylaxis of approximately
one week [1–5]. The studies are consistent in their
results, although the clinical significance of veno-
graphically detected DVT has been debated. The
prolonged risk period and the late occurrence of a
number of DVTs have led to relevant questions
about risk groups, optimal duration, clinical con-
sequences, and health economic implications. Sev-
eral studies have been published on the cost-effec-
tiveness of low molecular weight heparin (LMWH)
in the treatment [6–9] as well as prophylaxis
[6,10–13] of DVT.
Bergqvist et al. [5] studied the cost of prevent-
ing postoperative DVT with either unfractionated
heparin (UFH) or LMWH in patients undergoing
elective general abdominal surgery or elective hip
surgery. General prophylaxis with LMWH was
the most cost-effective strategy when prophylaxis
was given for one week.
All previous economic evaluations were model-
ing studies in which different profiles (strategies)
for patient management were constructed in terms
of decision trees, and assumptions were made
about probabilities of different outcomes. Thus,
the results were uncertain, although extensive sen-
sitivity analysis was performed to test the robust-
ness of the conclusions [14,15].
The purpose of this study was to investigate the
cost-effectiveness of prolonged prophylaxis with
enoxaparin after elective hip surgery, based on
cost and effectiveness data from one of the studies
on prolonged thromboprophylaxis [1].
 
Method
 
The trial compared in-hospital prophylaxis with
prolonged prophylaxis. All patients received pro-
phylaxis with enoxaparin for an average of 9 days
and were then randomized to continuous prophy-
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laxis with enoxaparin (40 mg daily) or placebo
until bilateral venography was performed 19 to 23
days after discharge.
The clinical trial showed improved effectiveness
(that is, fewer DVTs), in the intervention group
[1]. The baseline outcomes are given in Table 1.
The two prophylactic alternatives can be evalu-
ated in a cost-effectiveness analysis.
There are two problems with this methodology.
First, the effectiveness measure, venographic DVT,
is a surrogate end point, which is difficult to inter-
pret for decisions about resource allocation. If
there is a net cost for the intervention, a compari-
son must be undertaken with the value of re-
sources in alternative uses. It is therefore necessary
to translate the surrogate end point into a more
meaningful end point, like the number of life-years
gained. However, there were no mortality differ-
ences between the two arms, a difference not pos-
sible to detect with a realistic sample size. One al-
ternative may then be to model gains in life
expectancy from either a significant reduction in
DVTs or a nonsignificant reduction in the number
of pulmonary embolisms (PE). There were two
PEs in the placebo group and none in the enox-
aparin group. If we assume that PE is fatal in 2%
of cases, 0.04 deaths were avoided in the enox-
aparin arm; that is, 0.0003 deaths per treated pa-
tient (Intention to treat (ITT) 131 patients). This
results in three deaths avoided per 10,000 treated
patients, compared to four deaths avoided in the
study by O’Brien et al. [15]. Assuming a life ex-
pectancy of 10 years, the number of life-years
gained per patient is 0.003. If the calculated net
cost is divided by 0.003, we will get the cost per
life-year gained. In the clinical trial, the average
age of the patients was 68.5 years; 43% of the pa-
tients were men. The average life expectancy in
Sweden for a man was 13.6 years at age 68 and
12.9 years at age 69 for the period 1991 to 1995
[16]. For women, the figures were 17.0 and 16.2
years, respectively. Weighed with their relative
shares in the study, the average life expectancy of
the patients was 15.2 years. Assuming that the life
expectancy in the study population is the same as
in the normal population, the gain in life expect-
ancy from a reduction in the number of PEs would
amount to 0.0046 life-years gained per treated pa-
tient. Our estimated gain in life expectancy is con-
servative, both in terms of the risk reduction and
the life expectancy of the subjects. Using the esti-
mate by O’Brien et al. for risk reduction and nor-
mal life expectancy will exactly double the num-
ber of life-years gained, thus reducing the cost per
life-year gained to half (see Table 5).
Second, the costs for the intervention in the clini-
cal trial may differ from the actual costs in ordinary
clinical practice. By definition, a clinical trial is not
ordinary clinical practice. In addition, placebo is
not an accepted treatment alternative. Some devia-
tions must be made from the clinical trial in order
to calculate a realistic value of the potential costs of
prolonged prophylaxis. When these deviations are
made in order to improve on the external validity,
the internal validity is reduced. The effectiveness is
determined by the differences between the placebo
and the intervention group. When we make certain
changes on the cost side, these changes may have a
bearing on the effectiveness. Let us therefore take
these assumptions step by step.
We assume that in the alternative to prolonged
enoxaparin prophylaxis, there are no intervention
costs, i.e., when no prophylaxis is given, there are
no intervention costs. In the trial, placebo patients
got injections with the same administration costs
as the intervention group. The actual difference
was only the cost of the active substance. In the
study, patients were given injections by a research
 
Table 1
 
Descriptive baseline statistics from the study on prolonged prophylaxis by Bergqvist et al. [1].
 
Enoxaparin Placebo
Number of patients 131 131
Number of DVTs 
 

 
 PEs (per patient) 21 (0.16) 45 (0.34)
Number of clinical DVTs (per patient) 2 (0.015) 7 (0.053)
Number of PEs 0 2
Number of treated patients (hospital admissions) 14 (10 due to DVT) 37 (35 due to DVT)
Number of hospital days for new admissions (all) 99 269
Number of hospital days due to DVT 78 262
Number of doses of enoxaparin or placebo
Hospitalization (open) 1274 1321 
Double-blind phase 2433 2372 
Doses per patient
Total 28.3 (28.2)
Double-blind 18.6 (18.1)
 
DVT, deep vein thrombosis; PE, pulmonary embolism.
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nurse. The costs for this were probably similar to
costs when district nurses give injections to pa-
tients in their homes. One alternative for calculat-
ing the administration costs would be to calculate
the cost of a nurse giving daily injections. How-
ever, most patients can be trained during the hos-
pital stay to self-inject and the administration
costs must be calculated outside the clinical trial.
The second part of the cost calculation is the
savings in the costs of treating DVTs. Data on the
number of hospital admissions and the number of
hospital days for treatment of DVTs were col-
lected during the clinical trial and used for the cal-
culation of the cost savings. However, this infor-
mation must be supplemented in different ways.
The costs of ambulatory treatment of DVTs are
not included. This may be estimated and added. A
more difficult problem is that the practice of treat-
ing DVTs as inpatients may have been changed af-
ter the completion of the clinical trial. As an alter-
native, all DVTs are treated on an outpatient
basis. One problem is that the DVTs were de-
tected through a phlebography, which is not part
of routine clinical management.
Cost-effectiveness is estimated as the net cost
per episode of DVT avoided, i.e., the incremental
cost-effectiveness ratio. Two different outcome
measures are used: total DVT and clinical DVT.
The net cost consists of the cost of enoxaparin and
its administration minus the costs for treatment of
DVT. If the net cost is negative, there is a domi-
nant solution to the decision problem, i.e., better
effectiveness and lower costs. If the net cost is pos-
itive, the study informs the decision-maker about
the cost per unit of outcome of the intervention,
the reduction in DVT.
Treatment costs are estimated in two ways. The
first method is to base the treatment costs on the
actual costs of treating these patients in the clini-
cal study. The second method is to assume that all
patients are treated as outpatients, which is indi-
cated as the most cost-effective treatment method.
Treatment costs in an outpatient setting will be
calculated, based on actual medical practice.
All calculations are carried out on an intention-
to-treat (ITT) basis. A problem is that not all ran-
domized patients are possible to evaluate. Effec-
tiveness and cost data thus can be based on the
evaluable patients only.
 
Data
 
From the original clinical study [1] the following
data were obtained:
1. The number of doses of enoxaparin during the
hospital stay (open-label period);
2. The number of doses of enoxaparin or placebo
during the randomization period;
3. The number of hospital days for treatment of
DVT;
4. The number of venographic DVTs and clinical
DVTs.
The number of DVTs was 21 in the enoxaparin
group and 43 in the placebo group. The number
of clinical DVTs were 2 and 7, respectively. In the
placebo group, 2 PEs were detected.
For calculation of treatment cost, we included
patients with a DVT that was actually treated. Pa-
tients with small muscle vein DVT were not
treated. PE was not screened for but was objec-
tively verified if suspected clinically (through scin-
tigraphy or angiography). There were no fatal PEs
in the study. Treatment was given to 35 patients in
the placebo group (including 2 PEs) and 10 pa-
tients in the enoxaparin group. In the enoxaparin
group, 8 patients were treated as inpatients and 2
as outpatients (i.e., a discharge is noted, but no
bed-days). In the placebo group, 4 patients were
treated as outpatients. A detailed account of the
patients in terms of DVT and treatment is given in
Table 2.
 
Estimation of Costs
 
The unit cost for enoxaparin amounts to 32.12
SEK for 40 mg in prepared syringes. The total cost
per patient is estimated by multiplying the cost per
 
Table 2
 
Bed-days for treated patients in the enoxaparin 
and placebo groups
 
Bed-days
Patients
(enoxaparin treatment)
Patients 
(placebo treatment)
0 2 4
4 0 2
5 1 3
6 1 8
7 1 3
8 0 5
9 2 4
10 1 0
11 1 3
15 0 1
17 0 1
21 1 0
29 0 1
Total, patients 10 35
Total, days 78 262
Days/patient 7.80 7.49
 
The two patients with pulmonary embolisms had 6 and 17 hospital days
respectively.
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dose with the number of doses. Since no increased
incidence of bleeding complications due to pro-
longed prophylaxis was seen in the trial, no addi-
tional costs for treatment of side-effects have been
included.
Assumptions about the extra costs for pro-
longed administration of enoxaparin must be
made. Our base case assumption is that 75% of
patients can self inject. The patients are instructed
how to do this during the hospital stay. No extra
costs for this are assumed, since it can be inte-
grated with the administration of the injections at
the hospital. The extra nursing time involved is
very small. However, we will assume that there is
a follow up visit after discharge to check the com-
pliance. For those who cannot self inject, we will
assume that the cost for the injection is equal to a
district nurse visit. Since most of the patients who
cannot self inject probably will have other health
care needs as well, we will make two assumptions
about the cost of the injection. The first is that the
cost is equal to the average cost of a nurse visit
(350 SEK), and the second is that it is equal to the
marginal cost; an additional 15 minutes of nursing
time at an approximate cost of 150 SEK per hour,
inclusive of indirect employer cost.
The cost for hospitalization due to treatment of
DVT is estimated by multiplying the total number
of days by the cost per hospital day. A cost of
3000 SEK is used, which is an average for cost per
hospital day in departments of orthopaedic sur-
gery. With an average number of hospital days of
7.5 (see Table 2), this amounts to 22,500 SEK per
hospitalized DVT. According to Swedish DRG-
prices, which are designed to mirror the average
cost, the price for DRG-code venous thrombosis
after hip replacement was 41,000 SEK in 1994
(Carl-Johan Muren, SPRI personal communica-
tion). The average length of stay for this DRG was
12.5 days. Using a DRG-cost per hospitalization
will therefore increase the savings from a reduc-
tion in hospitalizations. DRG-groups are not ho-
mogenous, however, and the study was performed
at a hospital that did not practice DRG-based
costing at the time of the study. It is therefore bet-
ter to use the actual number of bed-days as a basis
for costing. The DRG-based cost implies a cost
per bed-day or 3280 SEK, close to our estimate.
The cost for ambulatory treatment is calculated
as follows. Five days of treatment with enox-
aparin (1 mg per kilogram of body weight; aver-
age body weight of patients 80 kg); 2 
 

 
 58.50 
 

 
117 SEK per day for 5 days (585 SEK). To this we
add a visit to the outpatient department at 1500
SEK and one return visit at 750 SEK. We further
add a cost of 1000 SEK for treatment with war-
farin, including monitoring and expected costs for
treatment of bleeding. The total treatment cost
will therefore be 585 
 

 
 1500 
 

 
 750 
 

 
 1000 
 

 
3838 SEK. This is significantly lower than the cost
of 7765 SEK estimated in the study by Bergqvist et
al. [5]. However, it may be more realistic to as-
sume that in a strategy of ambulatory treatment,
patients on average will have one hospital day
[17]. Lindmarker and Holmström [9] estimated
the cost for treatment of DVT in an outpatient set-
ting as 7700 SEK compared to 18,000 if patients
were treated as inpatients. If we add the cost of a
phlebography, the cost will increase by 2411 SEK
(their estimate). Sahlgrenska Hospital had a price
of 2150 SEK for antegrade phlebography in 1996.
The total cost for ambulatory treatment used in the
calculations will be 7500 SEK, which includes one
phlebography and one hospital day at 1500 SEK.
In the clinical trial, phlebography was under-
taken in both the placebo and enoxaparin groups.
The costs are thus the same, and the cost of phle-
bography should not be added to the treatment
costs since we are looking at the differences be-
tween groups. If we estimate the costs for clinical
DVTs only, it is a different matter. In that case, we
should include the diagnostic costs. Since manage-
ment of patients according to clinical symptoms
involves diagnosis with negative findings, we will
add the cost of two extra phlebographies and vis-
its, assuming that one third of phlebographies are
positive, which has been shown to be the case in
Malmö (366 DVT of 1006 phlebographies) [18].
This will mean a cost of 7500 
 

 
 4300 
 

 
 3000 
 

 
14,800 SEK per clinical DVT. For PE we will use
the cost estimate by Bergqvist of 65,000 SEK per
case [5]. This estimate is based on data from the
same hospital where the patients were treated.
 
Results
 
Table 3 shows the total and average cost for pa-
tients in the enoxaparin and placebo groups, re-
spectively. The cost of enoxaparin during hospi-
talization is included in the study despite the fact
that this cost is “sunk cost” when the randomiza-
tion is done. However, the costs are similar be-
tween the two groups. Hospitalization costs for
patients without a DVT have been excluded. For
patients with a discharge but no hospital days a
cost for ambulatory treatment (7500 SEK) has
been added.
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The extra cost for prolonged prophylaxis is 597
SEK per patient, or 585 SEK when taking into ac-
count that the cost during hospitalization was
slightly lower. (585 SEK will be used in the fol-
lowing calculations). The savings in hospital costs
amount to 525,000 SEK, or 4008 SEK per patient.
This means that there is a net saving per patient
of 3423 SEK, calculated on an ITT basis. How-
ever, cost for administration of enoxaparin is not
included in the calculation. If the cost for adminis-
tration is lower than 3423 SEK, the intervention
will be cost saving.
Enoxaparin was administered for an average of
18.6 days (doses). To be cost-effective, the cost of
administration must not exceed 184 SEK per dose.
In the clinical study, enoxaparin was administered
by a research nurse. This resulted in extremely
good compliance, which contributed to the effec-
tiveness achieved. In practice, this is equivalent to
administration by a district nurse. The average
cost per visit of a district nurse is 350 SEK.
Table 4 shows the cost per DVT and clinical
DVT avoided with different assumptions about
the proportion of patients who can self-administer
the injection, assuming that the injection other-
wise is given by a district nurse.
Table 5 shows calculations of cost-effectiveness
for the following assumptions: administration
costs of 350 SEK for 75% of patients and 350
SEK per injection for the rest of the patients (total
cost 6510 SEK). A sensitivity analysis is under-
taken, assuming the cost of injection by nurse is
estimated at marginal cost 37.50 SEK per injec-
tion. No costs for treatment of side-effects are as-
sumed, since there were no bleeding complications
reported in the intervention group. Cost savings
from reductions in treatment costs have been cal-
culated in three ways: (1) as actual costs for inpa-
tient care in the clinical trial; (2) assuming that all
patients were treated as outpatients; and (3) as-
suming that only clinical DVTs and PEs were
treated.
When the marginal scenario for administration
of enoxaparin is used, the intervention is cost-sav-
ing for all alternatives for calculating cost savings.
 
Discussion
 
This study reports results from an economic evalu-
ation of prolonged prophylaxis based on outcome
data from a clinical trial [1]. There are by now
 
Table 3
 
Total and average costs and number of events per patient
 
Enoxaparin prolonged 
prophylaxis cost (SEK)
Enoxaparin standard
prophylaxis cost (SEK)
Hospitalization cost 
(SEK)
Number
of DVTs
Number of 
clinical events
Total
Enoxaparin group 78,148 40,921 319,500 21 2
Placebo group 42,431 844,500 45 9
Average per patient
Enoxaparin group 597 312 2439 0.1603 0.0153
Placebo group — 324 6447 0.3435 0.0687
 
DVT, deep vein thrombosis; PE, pulmonary embolism.
 
Table 4
 
Cost per DVT and clinical DVT avoided under 
different assumptions about the share of patients who can 
self-administer the injection
 
Share of patients
Cost of DVT 
avoided (SEK)
Cost per clinical DVT
avoided (SEK)
0% 16,850 57,771
25% 7,966 27,314
50% Cost-saving Cost-saving
75% Cost-saving Cost-saving
 
DVT, deep vein thrombosis.
 
Table 5
 
Cost-effectiveness of prolonged prophylaxis 
under different assumptions
 
Intervention cost per patient (SEK) 2487
Marginal cost estimate (597 SEK 
 

 
 437 SEK) 1034
Cost savings from reduced treatment costs
Reduced hospitalizations according to the clinical
trial (SEK)
4008
Reduced costs estimated for ambulatory 
treatment (SEK)
1374
Reduced costs for treating clinical DVT and
PE only (SEK)
1783
Outcome
Number of DVTs avoided 0.1832
Number of clinical DVTs avoided 0.0534
Cost-effectiveness
Dominated
6075 SEK per DVT avoided
13,184 SEK per clinical DVT avoided
Cost per life-year gained (SEK)
 
*
 
235,000
Cost per life-year gained (SEK)
 
†
 
120,000
 
*
 
Based on assumptions about the relation between PE and reductions in sur-
vival; 0.003 life-years gained per patient in the study. Net cost estimate after
cost of treating clinical DVT/PE (i.e. only costs for treatment of clinical DVTs
are included in the savings).
 
†
 
Based on an assumption of a gain in life expectancy of 0.006 life-years per
treated patient.
DVT, deep vein thrombosis; PE, pulmonary embolism.
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four studies that consistently show a significant re-
duction in venographically diagnosed DVT with
prolonged prophylaxis after elective hip surgery
[1–4]. One important question is whether this new
concept is cost-effective. One of the studies [1] has
been used as a model for such an analysis. The ac-
tual amounts of the drug (enoxparin) adminis-
tered as well as the actual number of hospital days
consumed for treatment of DVT have been used
for the calculation of costs, which have been re-
lated to the clinical outcome measures in the
study. The clinical trial setting gives the study a
high internal validity. Observed differences are re-
lated to the differences between the intervention
and placebo group. However, there are also limi-
tations due to the clinical trial setting. First, enox-
aparin was administered by a research nurse,
which is not a relevant alternative in ordinary clin-
ical practice. In a sensitivity analysis, the conse-
quences of more realistic assumptions about ad-
ministration costs were therefore evaluated. It
may be argued that we also should reduce the
compliance, when the drug is administered in or-
dinary clinical practice. A reduction in compliance
will, however, affect costs as well as outcome, un-
less we assume that the patients are supplied with
the drug but are not taking it. The main problem
with a reduced compliance is not cost-effectiveness
for those treated but rather that the potential gains
of the prophylaxis will not reach all that can bene-
fit from it. Since the cost-effectiveness is rather
high, it may also be cost-effective to spend enough
resources to secure a good compliance.
A second limitation of the trial setting is the as-
sessment of outcome with phlebography in all pa-
tients, which is not used in clinical practice. One
consequence is the difficulty in validating that the
resources spent for treatment of DVT are relevant
for the clinical situation. Ideally, the clinical study
would have included a third arm, in which pa-
tients were managed according to ordinary clinical
practice. We have tried to investigate this by mak-
ing several sensitivity analyses. A more difficult
problem is to assess the real patient benefits from
the intervention. A clinical trial will never have
enough patients to show a difference in number of
(quality-adjusted) life-years gained. We are there-
fore forced into the same solution as other re-
searchers, to model the potential health gains from
reductions in DVT and PE. The epidemiological
information for doing this is limited. It is an ad-
vantage that the results show that prolonged pro-
phylaxis is a dominant strategy, giving benefits at
a lower cost, in most of the scenarios investigated.
 
Conclusions
 
Prolonged prophylaxis is cost-saving in the clinical
study used for the economic evaluation. The ac-
tual costs for treating DVT were higher than the
costs for the drug. The net saving per patient was
3400 SEK, which means that if the administration
costs are lower than this, the intervention will be
cost-saving. The cost-effectiveness is sensitive to
the cost of administration. The conclusion on
cost-effectiveness of prolonged prophylaxis is sup-
ported by results from a decision-analysis model
[19].
When it is assumed that the cost for treatment
is reduced in an outpatient setting, the interven-
tion is still cost-saving under these assumptions.
The cost for administration should not exceed
those of initial patient training at the hospital and
one follow-up visit by a district nurse to ensure
compliance.
The trial was too small to detect significant dif-
ferences in PE. However, if we use the nonsignifi-
cant difference in PE, the cost per life-year gained,
assuming that 75% of patients can self-inject, was
235,000 SEK.
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